Century Therapeutics Terminates Material Agreement
Ticker: IPSC · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1850119
Sentiment: neutral
Topics: agreement-termination, material-event
TL;DR
Century Therapeutics just terminated a major deal, details TBD.
AI Summary
On December 12, 2024, Century Therapeutics, Inc. reported the termination of a material definitive agreement. The filing does not specify the counterparty or the nature of the agreement, but it indicates a significant event for the company.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, partnerships, and financial standing.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement often signals underlying issues or strategic shifts that could affect the company's future performance.
Key Players & Entities
- Century Therapeutics, Inc. (company) — Registrant
- December 12, 2024 (date) — Date of earliest event reported
- 20241213 (date) — Filing Date
FAQ
What specific material definitive agreement was terminated by Century Therapeutics, Inc.?
The filing states that a material definitive agreement was terminated, but does not specify which agreement.
Who was the counterparty to the terminated material definitive agreement?
The filing does not disclose the identity of the counterparty to the terminated agreement.
What is the effective date of the termination of the material definitive agreement?
The filing reports the termination as of December 12, 2024.
Does the termination of this agreement have any immediate financial implications disclosed in the filing?
The filing does not detail any immediate financial implications resulting from the termination.
Are there any other material events reported by Century Therapeutics, Inc. on December 12, 2024?
This 8-K filing specifically reports the termination of a material definitive agreement as the event.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-12-13 17:00:18
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share IPSC Nasdaq Global Select
Filing Documents
- tm2431062d1_8k.htm (8-K) — 26KB
- 0001104659-24-128491.txt ( ) — 197KB
- ipsc-20241212.xsd (EX-101.SCH) — 3KB
- ipsc-20241212_lab.xml (EX-101.LAB) — 33KB
- ipsc-20241212_pre.xml (EX-101.PRE) — 22KB
- tm2431062d1_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, Pharm.D. Name: Brent Pfeiffenberger, Pharm.D. Title: President and Chief Executive Officer Date: December 13, 2024